Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

PURPOSE: To determine whether adding the multidrug resistance gene-1 (MDR-1) modulator valspodar (PSC 833; Novartis Pharmaceuticals, Hanover, NJ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). PATIENTS A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Greenberg, Peter L., Lee, Sandra J., Advani, Ranjana, Tallman, Martin S., Sikic, Branimir I., Letendre, Louis, Dugan, Kathleen, Lum, Bert, Chin, David L., Dewald, Gordon, Paietta, Elisabeth, Bennett, John M., Rowe, Jacob M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2004
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457168/
https://ncbi.nlm.nih.gov/pubmed/15020609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2004.07.048
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados